Evaluation of antimicrobial resistance and treatment failures for Chlamydia trachomatis: A meeting report

Journal of Infectious Diseases

Volumn 191, Issue 6, 2005, Pages 917-923

  Wang, Susan A ^a,e   Papp, John R ^a   Stamm, Walter E ^b   Peeling, Rosanna W ^d   Martin, David H ^c   Holmes, King K ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CYCLOHEXIMIDE; DOXYCYCLINE; FOLIC ACID ANTAGONIST; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; CELL CULTURE; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CLINICAL TRIAL; EVALUATION; HUMAN; INFERTILITY; LABORATORY TEST; METHODOLOGY; NONHUMAN; PELVIC INFLAMMATORY DISEASE; PRIORITY JOURNAL; REVIEW; SWINE; TREATMENT FAILURE; UNITED STATES;

ANIMALS; ANTI-BACTERIAL AGENTS; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MICE; MICROBIAL SENSITIVITY TESTS; TREATMENT FAILURE;

EID: 14844320488     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/428290     Document Type: Review

References (40)

1. Groseclose SL, Zaidi AA, DeLisle SJ, Levine WC, St Louis ME. Estimated incidence and prevalence of genital Chlamydia trachomatis infections in the United States, 1996. Sex Transm Dis 1999; 26:339-44.
2. Institute of Medicine, Division of Health Promotion and Disease Prevention. The hidden epidemic: confronting sexually transmitted diseases. Eng TR, Butler WT, eds. Washington, DC: National Academy Press, 1997.
3. Whittington WLH, Kent C, Kissinger P, et al. Determinants of persistent and recurrent Chlamydia trachomatis infection in young women. Sex Transm Dis 2001; 28:117-23.
4. Mourad A, Sweet RL, Sugg N, Schachter J. Relative resistance to erythromycin in Chlamydia trachomatis. Antimicrob Agents Chemother 1980; 18:696-8.
5. Lefèvre JC, Lépargneur JP. Comparative in vitro susceptibility of a tetracycline-resistant Chlamydia trachomatis strain isolated in Toulouse (France). Sex Transm Dis 1998; 25:350-2.
6. Somani J, Bhullar VB, Workowski KA, Farshy CE, Black CM. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis 2000; 181:1421-7.
7. Bragina EY, Gomberg MA, Dmitriev GA. Electron microscopic evidence of persistent chlamydial infection following treatment. J Eur Acad Dermatol Venereol 2001; 15:405-9.
8. Dessus-Babus S, Bébéar CM, Charron A, Bébéar C, de Barbeyrac B. Sequencing of gyrase and topoisomerase IV quinolone-resistance-determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained in vitro. Antimicrob Agents Chemother 1998; 42:2474-81.
9. Morrissey I, Salman H, Bakker S, Farrell D, Bébéar CM, Ridgway G. Serial passage of Chlamydia spp. in sub-inhibitory fluoroquinolone concentrations. J Antimicrob Chemother 2002; 49:757-61.
10. Suchland R, Stamm W, Denamur E, Rothstein D. C. trachomatis mutants resistant to rifampicin which map in the rpoB gene did not confer significant resistance to rifalazil [abstract CI-2130]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago, 14-17 September 2003). Washington, DC: American Society for Microbiology, 2003.
11. Dreses-Werringloer U, Padubrin I, Zeidler H, Köhler L. Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro. Antimicrob Agents Chemother 2001; 45:3001-8.
12. Dreses-Werringloer U, Padubrin I, Köhler L, Hudson AP. Detection of nucleotide variability in rpoB in both rifampin-sensitive and rifampin-resistant strains of Chlamydia trachomatis. Antimicrob Agents Chemother 2003; 47:2316-8.
13. Misyurina OY, Chipitsyna EV, Finashutina YP, et al. Mutations in a 23S rRNA gene of Chlamydia trachomatis associated with resistance to macrolides. Antimicrob Agents Chemother 2004; 48:1347-9.
14. Weiss E. Transaminase activity and other enzymatic reactions involving pyruvate and glutamate in Chlamydia (psittacosis-trachoma group). J Bacteriol 1967; 93:177-84.
15. Schachter J, Stamm WE. Chlamydia. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of clinical microbiology. Washington, DC: American Society for Microbiology, 1999:795-806.
16. Suchland RJ, Geisler WM, Stamm WE. Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp. Antimicrob Agents Chemother 2003; 47:636-42.
17. Ehret JM, Judson FN. Susceptibility testing of Chlamydia trachomatis: from eggs to monoclonal antibodies. Antimicrob Agents Chemother 1988; 32:1295-9.
18. Wyrick PB, Knight ST, Paul TR, Rank RG, Barbier CS. Persistent chlamydial envelope antigens in antibiotic-exposed infected cells trigger neutrophil chemotaxis. J Infect Dis 1999; 179:954-66.
19. Gérard HC, Köhler L, Branigan PJ, Zeidler H, Schumacher HR, Hudson AP. Viability and gene expression in Chlamydia trachomatis during persistent infection of cultured human monocytes. Med Microbiol Immunol 1998; 187:115-20.
20. Rice RJ, Bhullar V, Mitchell SH, Bullard J, Knapp JS. Susceptibilities of Chlamydia trachomatis isolates causing uncomplicated female genital tract infections and pelvic inflammatory disease. Antimicrob Agents Chemother 1995; 39:760-2.
21. Dickinson TM, Archer GL. Phenotypic expression of oxacillin resistance in Staphylococcus epidermidis: roles of mecA transcriptional regulation and resistant-subpopulation selection. Antimicrob Agents Chemother 2000; 44:1616-23.
22. Hartman BJ, Tomasz A. Expression of methicillin resistance in heterogeneous strains of Staphylococcus aureus. Antimicrob Agents Chemother 1986; 29:85-92.
23. Lenart J, Anderson AA, Rockey DD. Growth and development of tetracycline-resistant Chlamydia suis. Antimicrob Agents Chemother 2001; 45:2198-203.
24. Jones RB, Van Der Pol B, Martin DH, Shepard MK. Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics. J Infect Dis 1990; 162:1309-15.
25. Schmid G, Van der Pol B, Jones RB, Johnson R. Further investigating the clinical importance of heterotypic antimicrobial resistance in Chlamydia trachomatis. Int J STD AIDS 2001; 12(Suppl 2):41.
26. Notomi T, Ikeda Y, Nagayama A. Minimum inhibitory and minimal lethal concentration against Chlamydia trachomatis dependent on the time of addition and duration of the presence of antibiotics. Chemotherapy 1999; 45:242-8.
27. Dessus-Babus S, Belloc F, Bébéar CM, et al. Antibiotic susceptibility testing for Chlamydia trachomatis using flow cytometry. Cytometry 1998; 31:37-44.
28. Cross NA, Kellock DJ, Kinghorn GR, et al. Antimicrobial susceptibility testing of Chlamydia trachomatis using a reverse transcriptase PCR-based method. Antimicrob Agents Chemother 1999; 43:2311-3.
29. Peeling RW, Bowie WR, Dillon JR, et al. Standardization of antimicrobial susceptibility testing for Chlamydia trachomatis using a reverse transcriptase PCR-based method. In: Orfila J, Byrne GI, Chernesky MA, et al., eds. Chlamydial infections. Proceedings of the Eighth International Symposium on Human Chlamydial Infections (Chantilly, France) 1994; 346-9.
30. Peeling RW, Dillon JR, Black C, et al. Standardization of antimicrobial susceptibility testing (AST) for Chlamydia trachomatis (Ct) [abstract 275]. Proceedings of the 11th Meeting of the International Society for STD Research (New Orleans, 27-30 August 1995).
31. Ramsey KH, Miranpuri GS, Sigar IM, Ouellette S, Byrne GI. Chlamydia trachomatis persistence in the female mouse genital tract: inducible nitric oxide synthase and infection outcome. Infect Immun 2001; 69:5131-7.
32. Peeling RW, Patton DL, Cosgrove Sweeney YT, et al. Antibody response to the chlamydial heat-shock protein 60 in an experimental model of chronic pelvic inflammatory disease in monkeys (Macaca nemestrina). J Infect Dis 1999; 180:774-9.
33. Anderson AA and Rogers DG. Resistance to tetracycline and sulfadiazine in swine C. trachomatis isolates. In: Stephens RS, Byrne GI, Christiansen G, et al., eds. Chlamydial Infections. Proceedings of the Ninth International Symposium on Human Chlamydial Infection (Napa, CA) 1998; 313-6.
34. Dugan J, Rockey DD, Jones L, Andersen AA. Tetracycline resistance in Chlamydia suis mediated by genomic islands inserted into the chlamydial inv-like gene. Antimicrob Agents Chemother 2004; 48:3989-95.
35. Schillinger JA, Kissinger P, Calvet H, et al. Patient-delivered partner treatment with azithromycin to prevent repeated Chlamydia trachomatis infection among women. Sex Transm Dis 2003; 30:49-56.
36. Kramer MJ and Gordon FB. Ultrastructural analysis of the effects of penicillin and chlortetracycline on the development of a genital tract chlamydia. Infect Immun 1971; 3:333-41.
37. Ridgway GL, Owen JM, Oriel JD. The antimicrobial susceptibility of Chlamydia trachomatis in cell culture. Br J Vener Dis 1978; 54:103-6.
38. Johannisson G, Sernryd A, Lycke E. Susceptibility of Chlamydia trachomatis to antibiotics in vitro and in vivo. Sex Transm Dis 1979; 6:50-7.
39. Dreses-Werringloer U, Padubrin I, Jürgens-Saathoff B, Hudson AP, Zeidler H, Köhler L. Persistence of Chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitro. Antimicrob Agents Chemother 2000; 44:3288-97.
40. Stamm WE. Chlamydia trachomatis - the persistent pathogen. Sex Transm Dis 2001; 28:684-9.